Health Care · Services-Health Services

LFST LifeStance Health Group, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 184525798 filings
Russell 2000

LFST at a glance

LifeStance Health Group, Inc. (LFST, SEC CIK 1845257) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), LifeStance Health Group, Inc. (LFST) reported revenue of $1.4 billion (up 13.9% from FY2024) and net income of $9.7 million.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding LifeStance Health Group, Inc. (LFST) shares worth $1.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Burdick Kenneth A on November 16, 2026 of 124,228 shares at $14.31 per share.
  • In the last 90 days, LFST insiders reported 0 open-market purchases ($0) and 10 open-market sales ($758.8M) on Form 4, a net sale of $758.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.4B
+13.9% vs prior year
Insiders · 90 days
0 buys · 10 sells
Net −$758.8M
13F holders
32 funds
$1.6B · +0 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Nationwide outpatient mental healthcare platform employing 8,040 clinicians across 33 states with integrated virtual and in-person care
  • Strategic shift: Prioritized virtual visits leading to significant reduction of physical office footprint and closure of underoccupied centers in 2023
  • Quantitative metric: 1.0 million unique patients treated in 2025 through approximately 9.0 million visits, with 87% having two or more visits
  • Emphasis on integrated care: Over 13 active integrated care programs partnering with primary care and specialists to unify mental and physical healthcare
  • Noteworthy fact: 90% of revenue derived from commercial in-network payors, enhancing affordability and access through extensive payor contracts

Risk Factors

  • Regulatory risk from the No Surprises Act (effective Jan 1, 2022) causing payment disputes and penalties for billing and provider directory inaccuracies
  • Geopolitical/macroeconomic exposure from 29% revenue concentration with UnitedHealthcare (14%) and Elevance Health (15%), risking impact from reimbursement changes
  • Operational vulnerability in clinician recruitment and retention amid rising labor costs and potential unionization increasing expenses and turnover
  • Competitive threat from emerging AI and machine learning technologies reducing demand for licensed clinician care, impacting patient volumes
  • Financial risk from high capital expenditures on new centers leading to margin pressure until patient visits generate revenue

Management Discussion & Analysis

  • Cash and cash equivalents $248.6M in 2025 vs $154.6M in 2024; operating cash flow $146.2M in 2025 vs $107.3M in 2024
  • Debt outstanding $282.8M in 2025 vs $290.0M in 2024 under 2024 Credit Agreement; compliance with leverage and interest coverage covenants
  • Investing cash outflow $36.1M for property and equipment in 2025 vs $21.6M in 2024; financing activities used $16.0M in 2025 vs $9.9M in 2024 due to loan repayments and equity award settlements
  • No explicit revenue or profit margins disclosed in excerpt; reported $9.7M net income in 2025 vs $57.4M net loss in 2024 mentioned in cash flow section
  • Management expects existing cash sufficient for 12 months; growth, acquisitions, and market expansion are key risks requiring potential additional financing

AI summary of the LFST 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Ownership concentration: TPG and Summit collectively own approximately 25.3%, limiting stockholder influence over control transactions
  • Governance transition: Loss of Nasdaq controlled-company status triggered phased independent committee requirements over one year
  • Compliance exposure: Governance exemptions remain available during the transition, reducing stockholder protections
  • Conflict risk: Principal Stockholders may invest in competitors or pursue acquisitions unavailable to LifeStance

Management Discussion & Analysis

  • Revenue $455.9M, up 25% YoY from $363.8M, driven by 17% higher visits and modest payor rate increases
  • Operating margin 7.3% vs 2.0% YoY, with income from operations $33.1M vs $7.4M
  • Center Margin $161.4M vs $116.6M, up 38%; Adjusted EBITDA $68.4M vs $40.2M
  • Nine-month operating cash flow $170.0M vs $88.6M; share repurchases $24.8M during the quarter
  • Outlook: revenue growth from clinician recruiting, acquisitions, new centers and virtual sessions; near-term center and G&A investment headwinds

AI summary of the LFST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 8.01: Other Events

  • Secondary offering of 45,000,000 shares, entirely sold by existing stockholders
  • LifeStance received no proceeds, limiting direct balance-sheet benefit
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results announced for period ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, guidance and operating metrics

Item 7.01: Regulation FD Disclosure

  • Exhibit 99.2 contains supplemental LifeStance Health Group information for investor review
  • Presentation details may provide additional operating or financial context beyond the 8-K filing

Item EX-99.1: Item EX-99.1

  • Q3 revenue $455.9M, up 25%, driven by 17% higher visits, clinician growth and improved revenue per visit
  • Net income $22.4M versus $1.1M, while Adjusted EBITDA rose 70% to $68.4M

Item EX-99.2: Item EX-99.2

  • Q3 revenue $455.9M, up 25% year over year, with visits up 17% to 2.7M and clinicians up 11% to 8,863
  • Center Margin $161.4M, or 35.4%, versus 32.0% year over year, signaling improved delivery economics
Filed Oct 16, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Teresa DeLuca, M.D. resigning from board and all committees effective December 31, 2026
  • Departure not related to disagreement, reducing immediate governance concern

AI summaries of LFST 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LFST

Don't miss the next LFST filing

  • Alerts as it files. A push when LFST files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LFST, by share count.
  • Ask anything. An AI agent that reads every LFST filing and answers with sources.

LFST alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Burdick Kenneth ASellNov 16, 2026$14.31
Burdick Kenneth AMNov 12, 2026$7.61
Burdick Kenneth AFNov 12, 2026$14.31
Burdick Kenneth AMNov 12, 2026-
Burdick Kenneth ASellNov 12, 2026$14.31
TPG GP A, LLCSellNov 12, 2026$13.02
Miller Lisa KSellNov 11, 2026$14.68
Burdick Kenneth AMNov 10, 2026$7.61

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$1.1B$1.3B$1.4B
Operating Income-$189.1M-$31.6M$24.1M
Net Income-$186.3M-$57.4M$9.7M
Op. Margin-17.9%-2.5%1.7%
Net Margin-17.6%-4.6%0.7%
Balance Sheet
Total Assets$2.1B$2.1B$2.2B
Equity-$1.4B$1.5B
ROE--4.0%0.6%
Cash Flow
Operating CF-$16.9M$107.3M$146.2M
CapEx$40.5M$21.6M$36.1M

Source: XBRL data in LifeStance Health Group, Inc. (LFST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LFST share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LFST shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$1.57B
Q2 202632$1.79B
Q1 202631$847.9M
Q4 202527$798.4M
Q3 202528$557.8M
Q2 202527$472.6M
Q1 202525$537.2M
Q4 202418$479.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 220 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LFST filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
8-KNov 12, 2026Analysis-
4Nov 12, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
8-KOct 16, 2026Analysis-
4Sep 24, 2026--
4Sep 15, 2026--
8-KSep 11, 2026Analysis-
4Sep 4, 2026--
4Sep 4, 2026--
4Aug 26, 2026--
4Aug 18, 2026--
4Aug 14, 2026--
4Aug 13, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
SC 13GJul 29, 2026-

Related Health Care companies

All Health Care →

LFST SEC filings: frequently asked questions

Are LFST insiders buying or selling?

In the last 90 days, LifeStance Health Group, Inc. (LFST) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $758.8 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LFST stock?

As of September 30, 2026, the largest LifeStance Health Group, Inc. (LFST) holders among the 13F filers tracked by SignalX were BlackRock ($490.3 million), Vanguard Portfolio Management LLC ($210.1 million), Vanguard Capital Management LLC ($136.9 million), T. Rowe Price Group ($120.9 million), State Street Corp ($118.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LFST's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), LifeStance Health Group, Inc. (LFST) reported revenue of $1.4 billion (up 13.9% from FY2024) and net income of $9.7 million. The figures come from the XBRL data in the 10-K.

What are the main risks in LFST's latest 10-K?

In the 10-K filed February 25, 2026, LifeStance Health Group, Inc. (LFST) flagged: Regulatory risk from the No Surprises Act (effective Jan 1, 2022) causing payment disputes and penalties for billing and provider directory inaccuracies. Geopolitical/macroeconomic exposure from 29% revenue concentration with UnitedHealthcare (14%) and Elevance Health (15%), risking impact from reimbursement changes. (AI summary of the Risk Factors section.)

What did LFST report in its latest 8-K?

LifeStance Health Group, Inc. (LFST) filed an 8-K on November 12, 2026 reporting Item 8.01 (Other Events). Secondary offering of 45,000,000 shares, entirely sold by existing stockholders.

What are the latest LFST SEC filings?

LifeStance Health Group, Inc. (LFST) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.

What is LFST's SEC CIK number?

LifeStance Health Group, Inc. (LFST)'s SEC Central Index Key (CIK) is 1845257. EDGAR lists every LFST filing under that number.

Ask anything about LFST

The research agent reads LFST's filings, financials, insider trades and 13F holders, then answers with sources.